^
Association details:
| Biomarker: | CCDC6-RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | nintedanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Excerpt:
Responses were observed with cabozantinib, vandetanib, sunitinib, lenvatinib, and nintedanib, but not with sorafenib, alectinib, ponatinib, or regorafenib (Table 2)….Response to therapy was noted in three patients with non-KIF5B fusion partners, including two with CCDC6-RET...
DOI:
10.1200/JCO.2016.70.9352
